Intended Audience: All neonatal nurses
NCC Codes: NIC3, NNP4, LRN4

Objectives: Upon completion, learners will be able to:

Define pharmacogenomics and terms associated with this field of medicine.
Discuss how genetic variations can impact drug metabolism.
Identify how genetic variations can alter drug response (toxicity and efficacy).

Learning Outcome: Learners will gain knowledge regarding the science of pharmacogenomics and how it may apply to neonates in the future.

Requirements for Completion: The following requirements are necessary for successful completion of this CNE activity.

Participants must be registered for the conference.
Attend at least 90% of each session.
Complete evaluations to earn continuing professional development contact hours.

Accreditation

The Academy of Neonatal Nursing is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

Provider, Academy of Neonatal Nursing, approved by the California Board of Registered Nursing, Provider #CEP 6261; and Florida Board of Nursing, Provider #FBN 3218, content code 2505.

Release Date: 4/27/2023
Expiration Date: 4/30/2026

Disclosures:

The speakers, nurse planners, planning committee, and content reviewers have no relevant financial interests or affiliations with any ineligible companies.

Disclaimer: The Academy of Neonatal Nursing assumes no responsibility or liability for the content presented. Care of the infant should always be individualized and no one source relied upon for information regarding aspects of care. Accredited status does not imply endorsement by ANN, ANA, or the American Nurses Credentialing Center of any commercial products displayed or discussed in conjunction with an educational activity.

Lilly Yen PharmD, BCPPS

Pharmacist III, Children’s Hospital Los Angeles

Appearances